

Hydrocortisone sodium succinate –Risk of Tumor Lysis Syndrome

EDA performs label update to include the following:

Special warnings and precautions for use

In post marketing experience tumour lysis syndrome (TLS) has been reported in patients with malignancies, including haematological malignancies and solid tumours, following the use of systemic corticosteroids alone or in combination with other chemotherapeutic agents. Patients at high risk of TLS, such as patients with tumours that have a high proliferative rate, high tumour burden and high sensitivity to cytotoxic agents, should be monitored closely and appropriate precautions should be taken.

Background:

Tumor lysis syndrome (TLS) is **an oncologic emergency that is caused by massive tumor cell lysis with the release of large amounts of potassium, phosphate, and nucleic acids into the systemic circulation.**

Therapeutic indications

When oral therapy is not feasible, and the strength, form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, Cipla Hydrocortisone powder for injection is indicated for intravenous or intramuscular use in the following conditions:

1. Endocrine disorders
2. Rheumatic disorders
3. Collagen diseases
4. Dermatological diseases
5. Allergic states
6. Ophthalmic diseases
7. Gastrointestinal diseases
8. Respiratory diseases
9. Haematological disorders
10. Neoplastic diseases
11. Oedematous states
12. Miscellaneous

References: TGA ([Click here](#))